Wall Street analysts forecast that Vaxart Inc (NASDAQ:VXRT) will announce sales of $340,000.00 for the current quarter, according to Zacks. Two analysts have provided estimates for Vaxart’s earnings, with estimates ranging from $90,000.00 to $600,000.00. Vaxart posted sales of $1.77 million in the same quarter last year, which would indicate a negative year over year growth rate of 80.8%. The firm is scheduled to issue its next quarterly earnings results on Wednesday, February 5th.
On average, analysts expect that Vaxart will report full-year sales of $6.08 million for the current fiscal year, with estimates ranging from $5.67 million to $6.50 million. For the next financial year, analysts expect that the firm will post sales of $11.80 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Vaxart.
Vaxart (NASDAQ:VXRT) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.04. Vaxart had a negative return on equity of 115.71% and a negative net margin of 222.20%. The company had revenue of $0.45 million during the quarter, compared to analysts’ expectations of $0.44 million.
Several equities research analysts recently weighed in on the company. ValuEngine downgraded Vaxart from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Zacks Investment Research raised shares of Vaxart from a “hold” rating to a “buy” rating and set a $0.25 price objective on the stock in a research note on Thursday, November 21st. Brookline Capital Management assumed coverage on shares of Vaxart in a research note on Thursday, August 15th. They issued a “buy” rating and a $6.00 price objective on the stock. Finally, HC Wainwright restated a “buy” rating and set a $2.00 price objective on shares of Vaxart in a research report on Monday, November 18th.
Shares of NASDAQ:VXRT traded down $0.01 during trading on Thursday, reaching $0.32. The company had a trading volume of 200,900 shares, compared to its average volume of 555,984. Vaxart has a fifty-two week low of $0.25 and a fifty-two week high of $5.00. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.32 and a quick ratio of 2.32. The stock’s fifty day moving average price is $0.33 and its 200 day moving average price is $0.56. The firm has a market capitalization of $15.25 million, a price-to-earnings ratio of -0.12 and a beta of 0.58.
In other Vaxart news, insider Wouter Latour acquired 166,667 shares of the company’s stock in a transaction that occurred on Monday, September 30th. The shares were purchased at an average price of $0.30 per share, with a total value of $50,000.10. Also, major shareholder Armistice Capital Master Fund acquired 200,000 shares of the business’s stock in a transaction on Thursday, November 7th. The stock was acquired at an average price of $0.35 per share, with a total value of $70,000.00. Insiders have purchased 8,720,000 shares of company stock valued at $2,609,907 over the last three months. 7.30% of the stock is currently owned by corporate insiders.
Institutional investors have recently added to or reduced their stakes in the business. Sabby Management LLC boosted its position in shares of Vaxart by 30.1% during the 3rd quarter. Sabby Management LLC now owns 1,197,710 shares of the biotechnology company’s stock worth $430,000 after purchasing an additional 277,063 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Vaxart by 120.9% during the 2nd quarter. Renaissance Technologies LLC now owns 739,653 shares of the biotechnology company’s stock worth $496,000 after purchasing an additional 404,883 shares during the period. Finally, Vanguard Group Inc. increased its holdings in shares of Vaxart by 65.4% in the 2nd quarter. Vanguard Group Inc. now owns 89,209 shares of the biotechnology company’s stock valued at $60,000 after purchasing an additional 35,283 shares in the last quarter.
Vaxart Company Profile
Vaxart, Inc, a clinical-stage company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus.
Further Reading: What is a Backdoor Roth IRA?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.